VivoSeq
Oncology

Oropharyngeal Cancer

0

Pipeline Programs↗

18

Active Trials↗

2

Companies Involved↗

Oropharyngeal Cancer is an early-stage landscape with 0 programs across 2 companies. The most active players are Radiation Therapy Oncology Group, Hookipa Biotech GmbH.

Intelligence

Pipeline Metrics

Competitive Density

34/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

61/100

Attrition Rate

18/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Radiation Therapy Oncology Group logo

Radiation Therapy Oncology Group

0 programs

PreclinicalH

Hookipa Biotech GmbH

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

38

clinical trials

Completed11 · 29%
Recruiting11 · 29%
Terminated4 · 11%
Active, not recruiting4 · 11%
Withdrawn3 · 8%
Not yet recruiting3 · 8%
Other2 · 5%

Clinical Trials

Trial Activity

38 trials

Intratumoral Lidocaine Injection Before Oropharyngeal Cancer Surgery
Recruiting·—·Phase 1·NCT06747390·30 enrolled
Using CircuLating Tumor DNA to Risk Adapt Post-Operative Therapy for HPV-associated Oropharyngeal Cancer
Recruiting·—·Phase 2·NCT06445114·50 enrolled
SURVEILLE-HPV: Evaluation of HPV16 Circulating DNA as Biomarker to Detect the Recurrence, in Order to Improve Post Therapeutic Surveillance of HPV16-driven Oropharyngeal Cancers
Recruiting·UUNICANCER·Phase 2·NCT05582122·420 enrolled
Risk-adapted Therapy in HPV+ Oropharyngeal Cancer Using Circulating Tumor (ct)HPV DNA Profile - The ReACT Study
Recruiting·—·Phase 2·NCT04900623·145 enrolled
pBI-11 & TA-HPV (With Pembrolizumab as Treatment for Patients w/Advanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal Cancer
Recruiting·—·Phase 2·NCT05799144·54 enrolled
Assessment of Swallowing Function and Quality of Life in Oropharyngeal Cancer Patients Treated by Chemo-radiotherapy
Recruiting·JJules Bordet Institute·Phase 3·NCT04019548·110 enrolled
Phase 1 Clinical Trial of FluBHPVE6E7 Immunotherapy for HPV16-Associated Oropharyngeal Cancer
Recruiting·BBlueSky Immunotherapies GmbH·Phase 1·NCT06589609·12 enrolled
BALSTILIMAB on Viral Clearance in HPV+ Oropharyngeal Cancer Patients
Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT05363709·20 enrolled
Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal Cancer
Recruiting·OOhio State University Comprehensive Cancer Center·Phase 2·NCT06323460·45 enrolled
Testing Less Intensive Radiation With Chemotherapy to Treat Low-risk Patients With HPV-positive Oropharyngeal Cancer
Recruiting·UUniversity of Missouri-Columbia·Phase 2·NCT04444869·28 enrolled
A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer
Recruiting·—·Phase 1/2·NCT06319963·72 enrolled
Neoadjuvant Tislelizumab Plus Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (NeoSPOT)
Active, not recruiting·—·Phase 2·NCT06009861·110 enrolled
Trial of De-Intensified Post-operative Chemoradiation Following Robotic Surgery for HPV-positive Oropharyngeal Cancer
Active, not recruiting·—·Phase 2·NCT04502407·40 enrolled
Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer
Active, not recruiting·ECOG-ACRIN Cancer Research Group·Phase 2·NCT01898494·519 enrolled
CompARE: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC)
Active, not recruiting·UUniversity of Birmingham·Phase 3·NCT04116047·785 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)